References:
  1. Rawla, Prashanth et al. “Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma.” Endocrinology, diabetes & metabolism case reports  vol. 2017 17-0081. 4 Sep. 2017, doi:10.1530/EDM-17-0081
  2. Goldenberg, Ronald M et al. “SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.” Clinical therapeutics  vol. 38,12 (2016): 2654-2664.e1. doi:10.1016/j.clinthera.2016.11.002
  3. Roncon, Loris et al. “Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology  vol. 127 (2020): 104354. doi:10.1016/j.jcv.2020.104354
  4. Yan, Yongli et al. “Clinical characteristics and outcomes of patients with severe covid-19 with diabetes.” BMJ open diabetes research & care  vol. 8,1 (2020): e001343. doi:10.1136/bmjdrc-2020-001343
  5. Yang, Jin-Kui et al. “Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.” Acta diabetologica  vol. 47,3 (2010): 193-9. doi:10.1007/s00592-009-0109-4
  6. Munro, J F et al. “Euglycaemic diabetic ketoacidosis.” British medical journal  vol. 2,5866 (1973): 578-80. doi:10.1136/bmj.2.5866.578
  7. Vanelli, M et al. “The direct measurement of 3-beta-hydroxy butyrate enhances the management of diabetic ketoacidosis in children and reduces time and costs of treatment.” Diabetes, nutrition & metabolism  vol. 16,5-6 (2003): 312-6.
  8. “FDA Warns That SGLT2 Inhibitors for Diabetes May Result in a Serious Condition of Too Much Acid in the Blood.” FDA.gov , 2015, www.fda.gov/media/92185/download.
  9. Taylor, Simeon I et al. “SGLT2 Inhibitors May Predispose to Ketoacidosis.” The Journal of clinical endocrinology and metabolism  vol. 100,8 (2015): 2849-52. doi:10.1210/jc.2015-1884
  10. Qiu, Hongyu et al. “Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.” Diabetes/metabolism research and reviews  vol. 33,5 (2017): 10.1002/dmrr.2886. doi:10.1002/dmrr.2886
  11. Sampani, Erasmia et al. “Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.” BMC nephrology  vol. 21,1 276. 15 Jul. 2020, doi:10.1186/s12882-020-01930-6
  12. Yang et al., 2020, Cell Stem Cell 27, 125–136 July 2, 2020 ª 2020 Elsevier Inc. https://doi.org/10.1016/j.stem.2020.06.015
  13. Muniyappa, Ranganath, and Sriram Gubbi. “COVID-19 pandemic, coronaviruses, and diabetes mellitus.” American journal of physiology. Endocrinology and metabolism  vol. 318,5 (2020): E736-E741. doi:10.1152/ajpendo.00124.2020
  14. Iacobellis, Gianluca. “COVID-19 and diabetes: Can DPP4 inhibition play a role?.” Diabetes research and clinical practice  vol. 162 (2020): 108125. doi:10.1016/j.diabres.2020.108125
Consent : Informed consent was obtained from patient for the study.